February 18, 2013

CAS databases provide millions of journal article references from more than 10,000 major scientific journals worldwide, patent and patent family references from 63 patent authorities around the world, and other reputable web sources.  

The following patent record is from the CAplusSM database.

CAPLUS COPYRIGHT 2013 ACS

Patent Number: US 8318934
Title: A process for chiral resolution of 2-substituted 4-substituted 1,3-oxathiolanes via selective recrystallization
Inventor(s): Epa, Widanagamage Ruwansiri; Marcuccio, Sebastian Mario; Deadman, John Joseph
Patent Assignee(s): Avexa Limited, Australia
Source: PCT Int. Appl., 100pp. CODEN: PIXXD2
Language: English

Abstract:

The present invention relates to a novel process for the chiral resolution of 2-substituted 4-substituted 1,3-oxathiolanes and derivs. thereof.  In particular, the invention relates to resolution via selective recrystn. of a single stereoisomer from a diastereomeric mixture of the four possible stereoisomers. prepared nucleoside analogs, e.g., 2-benzoyloxymethyl-4-(N-benzoylcytosin-1-yl)-1,3-oxathiolane.  The compds. of interest are nucleoside analogs which are prepared  Thus, e.g., the optically active I was first prepared by reaction of 2-benzoyloxymethyl-1,3-oxathiolane-S-oxide with N-benzoylcytosine to provide a mixture of the cis/trans relative stereoisomers (2.86:1 cis/trans ratio) which underwent selective recrystn. in methanol to provide the pure 2-(R)-benzoyloxymethyl-4-(R)-(N-benzoylcytosin-1-yl)-1,3-oxathiolane (I).

View the full-text patent here.

Note: Titles and abstracts for patent records in CAplus are routinely enhanced to better describe the claimed invention. In this example, CAS enhanced both the abstract and title using additional information found in the patent. The original title of the U.S. granted patent is Process for chiral resolution of 2-substituted 4-substituted 1,3-oxathiolanes. For the CAplus record, this title was enhanced to read A process for chiral resolution of 2-substituted 4-substituted 1,3-oxathiolanes via selective recrystallization.

Recent News

       
    February 9, 2015 | Major New STN Release Delivers
    Essential Biomedical and Patent Content to IP
    Professionals
    
    January 26, 2015
 | Annual MEDLINE Reload on STN
    Features Enhanced Clinical Trial Information and the
    2015 MeSH Thesaurus
    
    January 23, 2015
 | STN Launches New Pricing
    Option for Information Brokers: Search Service
    Value Pricing
                               
  
                                                                     More News >> 

 Media Contact

 Name: Rhonda Ross
 Phone: 614-447-3624                                       
 Email: cas-pr@cas.org